Highest-materiality recent filing
Zach Scheiner resigned from the Board and all committees effective June 30, 2026.
Votes for Evert Schimmelpennink: 20,216,637; withheld: 230,219; broker non-votes: 3,995,212.
LENZ Therapeutics reports Q1 2026 net loss $41.5M, VIZZ product sales $1.7M
Q1 2026 product sales $1.7M from ~25,000 paid prescriptions, 19% increase over Q4 2025.
LENZ Therapeutics reports Q4 2025 net product revenue $1.6M from VIZZ launch; net loss $35.9M
Q4 net product revenue $1.6M from VIZZ aceclidine eye drop for presbyopia; over 20,000 filled prescriptions.
LENZ Q4 2025 prelim product rev $1.6M; >20K prescriptions for VIZZ launch
Net product revenue of ~$1.6M from VIZZ in first launch quarter (Q4 2025), with over 20,000 prescriptions filled.
FAERS report describes retinal tear in a patient using VIZZ (aceclidine ophthalmic solution) 1.44%.
LENZ Therapeutics Q3 2025 net loss $16.7M; VIZZ launch with 5K+ prescriptions in October
Net loss $16.7M ($0.59/share) vs $10.2M in Q3 2024; R&D spend down to $3.8M.
LENZ Therapeutics raises ~$80M via block trade of 1.75M shares at $45.75/shr
Sold 1,748,634 shares at $45.75/share for gross proceeds of ~$80M to a single investor.
LENZ Therapeutics launches VIZZ eye drop for presbyopia in U.S.; samples shipped
VIZZ (aceclidine 1.44%) first FDA-approved aceclidine-based eye drop for presbyopia, now commercially available.
LENZ Therapeutics receives FDA approval for VIZZ (aceclidine) to treat presbyopia
VIZZ (aceclidine ophthalmic solution) 1.44% approved by FDA for presbyopia, impacting ~128M US adults.
LENZ reports Q2 net loss $14.9M; LNZ100 PDUFA on track for Aug 8, 2025
Cash, cash equivalents and marketable securities $209.6M as of June 30, 2025; >$205M expected by PDUFA date.
LENZ Therapeutics annual meeting elects directors, ratifies auditor
17,983,676 of 27,544,520 shares represented at June 10, 2025 annual meeting.
LENZ Therapeutics Q1 net loss $14.6M; LNZ100 PDUFA on track for Aug 8, 2025
Net loss $14.6M ($0.53 per share) vs $16.6M ($3.53) YoY; R&D down to $5.8M, SG&A up to $11.1M.
Unaudited cash, cash equivalents and marketable securities approximately $194 million as of March 31, 2025.
LENZ Therapeutics enters into $150M ATM sales agreement with TD Cowen
Company entered Sales Agreement with TD Securities (USA) LLC to sell up to $150M common stock via ATM offering.
LENZ Therapeutics reports FY2024 net loss $49.8M; LNZ100 PDUFA set for Aug 8, 2025
FDA accepted NDA for LNZ100 (presbyopia); PDUFA target action date Aug 8, 2025; no advisory committee planned.
LENZ Therapeutics Q3 net loss $10.2M, cash $217.2M; LNZ100 NDA accepted, PDUFA Aug 8, 2025
Net loss $10.2M ($0.38/share) for Q3 2024 vs $18.9M ($9.62/share) in Q3 2023.
LENZ Therapeutics announces positive Phase 3 data for LNZ100 in China presbyopia trial
Primary endpoint met: 74% achieved ≥3-line improvement at 3 hours (p<0.0001 vs vehicle).
LENZ Therapeutics files NDA for LNZ100, reports Q2 net loss $10.3M, raises $30M via PIPE
NDA submitted to FDA for LNZ100 aceclidine eye drop for presbyopia, supported by positive Phase 3 CLARITY data.
LENZ submits NDA for LNZ100 (aceclidine) to FDA for presbyopia treatment
NDA supported by Phase 3 CLARITY study: met all primary and secondary near vision endpoints.
LENZ Therapeutics raises $30M from Ridgeback Capital in PIPE at $19/share
PIPE financing of $30M with Ridgeback Capital at $19.00 per share; expected to close July 17, 2024.
Net loss $16.6M ($3.53/share) vs $12.7M ($6.50/share) in Q1 2023; cash $213.3M.
LENZ Therapeutics: LNZ100 meets Phase 3 primary endpoint; 71% responder rate at 3 hours
Primary endpoint met: 71% of LNZ100 patients achieved ≥3-line improvement in near vision at 3 hours without distance loss (p<0.0001).
Graphite Bio completes reverse merger with LENZ Therapeutics, rebrands as LENZ, raises $53.5M PIPE
Merger closed March 21, 2024; Graphite renamed LENZ Therapeutics, Inc., ticker changes from GRPH to LENZ on March 22.
Stockholders approved 1-for-7 reverse stock split and name change to 'LENZ Therapeutics, Inc.' at March 14 special meeting.
Graphite Bio shareholders approve all merger-related proposals for Lenz deal
Proposal 1 (stock issuance and control change) passed: 40.9M for, 37k against, 7.5M broker non-votes.
Graphite Bio declares special $1.03/share dividend tied to Lenz merger
Special dividend estimated at $1.03 per share, capped at $60M.
Graphite Bio discloses supplemental proxy details to resolve merger-related shareholder lawsuits
Two federal lawsuits filed in CA and DE allege proxy omissions on LENZ financials, advisor conflicts; 12 additional demand letters received.
Graphite Bio clears HSR waiting period for merger with Lenz Therapeutics on Dec. 21
HSR waiting period under Hart-Scott-Rodino Act expired at 11:59 p.m. ET on December 21, 2023.
Graphite Bio to merge with Lenz Therapeutics; Lenz holders to own 65%
Graphite valued at $126.5M, LENZ at $231.6M; $60M cash dividend to pre-merger Graphite stockholders.
Subleases 32,113 sq ft of its 85,165 sq ft facility to Soleil Labs for $183,044/mo (first 12 mos) then $189,451/mo, term through Dec 31, 2024.
Separation agreement dated Sept 7, 2023 provides Tier 1 severance benefits under Executive Severance Plan.
Graphite Bio appoints new CEO, cuts 70% of workforce
Kimberlee C. Drapkin appointed President & CEO, effective Aug 21, 2023; base salary $550,000.
Graphite Bio appoints Kimberlee Drapkin as independent director
Board expanded from 10 to 11; Drapkin appointed effective July 28, 2023.
Graphite Bio shareholders elect three Class II directors, ratify Deloitte as auditor
Abraham Bassan, Matthew Porteus, and Jo Viney elected with >35.8M votes each; 5.6M broker non-votes.
Graphite Bio CFO Alethia Young resigns; CEO Josh Lehrer to assume PFO/PAO roles
Alethia Young resigns as CFO, effective June 30, 2023, to pursue other opportunities.
Discontinued development of nula-cel for sickle cell disease after serious adverse event (pancytopenia) in first dosed patient.
Graphite Bio enters retention agreements with senior management amid strategic review
Retention agreements cover CEO, CFO, and other senior executives, providing lump sum cash equal to 50% of annual base salary upon qualifying termination or Feb 22, 2024.
Discontinues development of nula-cel for sickle cell disease; exploring external continuation.
First patient dosed with nula-cel experienced prolonged pancytopenia requiring ongoing transfusion and growth factor support.
Preclinical data presented at ASH on single-cell RNA sequencing method to assess gene correction in reticulocytes.
Graphite Bio doses first patient with nula-cel; Q3 net loss $24.7M; cash runway into Q4 2024
Dosed first sickle cell patient with nula-cel; initial proof-of-concept data on track for mid-2023.
Graphite Bio announces two abstracts accepted for ASH 2022 annual meeting
Abstract #5965 describes beta-globin gene replacement strategy for beta-thalassemia using UltraHDR platform.
First patient dosed with nula-cel (formerly GPH101) in Phase 1/2 CEDAR trial for sickle cell disease.
Graphite Bio doses first SCD patient with nula-cel; Q2 net loss $25.9M, cash $328.3M
Dosed first patient in Phase 1/2 CEDAR trial of nula-cel for sickle cell disease; initial proof-of-concept data expected mid-2023.
GPH102 gene replacement achieved homology directed repair (HDR) rates up to 40% in sickle cell HSPCs and restored adult hemoglobin (HbA) expression.
Graphite Bio stockholders elect three Class I directors and ratify auditor at 2022 Annual Meeting
Stockholders elected Jerel Davis, Perry Karsen, and Joseph Jimenez as Class I directors; each received >37M votes for, ~3M withheld.
Graphite Bio presents preclinical GPH102 data for beta-thalassemia; HDR rates up to 40%
Preclinical gene replacement data for GPH102 presented at ASGCT; HDR rates up to 40% in sickle cell HSPCs restoring HbA expression.
Graphite Bio Q1 net loss $25.8M; on track to dose first SCD patient in H2 2022
Net loss $25.8M ($0.48 per share); R&D spend $18.2M, G&A $7.7M.
Graphite Bio reports FY2021 net loss $70.8M; GPH101 first patient dosing delayed to H2 2022
Cash, equivalents, restricted cash $378.7M as of Dec 31, 2021; runway into Q4 2024.
Effective as of the Effective Time, Frederic Guerard and James McCollum were appointed as Class I directors
Zach Scheiner were appointed as Class III directors
Jeff George, Shelley Thunen, and Evert Schimmelpennink were appointed as Class II directors
Jeff George, Shelley Thunen, and Evert Schimmelpennink were appointed as Class II directors
Effective as of the Effective Time, Frederic Guerard and James McCollum were appointed as Class I directors
Also on March 21, 2024, Mr. George was appointed as the Chair of the Board.
Jeff George, Shelley Thunen, and Evert Schimmelpennink were appointed as Class II directors
effective as of August 21, 2023 (the “Termination Date”), Josh Lehrer, M.D., the former President, Chief Executive Officer and member of the Board of Directors of Graphite Bio, Inc. (the “Company”), separated from his employment and all officer and director positions with the Company.
On July 28, 2023, the Board of Directors (the “Board”) of Graphite Bio, Inc. (the “Company”) increased the size of the Board from ten to eleven members and appointed Kimberlee C. Drapkin as a director of the Company, effective immediately
On June 19, 2023, Alethia Young, the Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of Graphite Bio, Inc. (the “Company”), notified the Company of her decision to resign, effective at the close of business on June 30, 2023.
The Company intends to appoint Josh Lehrer, the Company’s Chief Executive Officer, to serve as the Company’s Principal Financial Officer and Principal Accounting Officer effective immediately following Ms. Young’s departure.
On March 2, 2022, Graphite Bio, Inc. (the “Company”) announced the hiring and appointment of Alethia Young as Chief Financial Officer.
Max materiality 1.00 · Median 0.65 · Most common event other_material